Goldman Sachs Starts Phathom Pharmaceuticals (PHAT) at Neutral
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $9.58 +4.36%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Neutral rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $24.27 yesterday.
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
